Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: GlobalData
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Daiichi Sankyo Co Ltd's Subsidiary Submits NDA for Cell-Based Pandemic Flu Vaccine- Pharma Japan

Sunday, 30 Jun 2013 08:00pm EDT 

Pharma Japan reported that Daiichi Sankyo Co Ltd announced that its subsidiary Kitasato Daiichi Sankyo Vaccine has filed a new drug application (NDA) on June 19, 2013 for the cell-based pandemic influenza vaccine.